stockrow
Wednesday 11 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
13.12
0.03
−0.23%
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Net income
Vir Biotechnology, Inc.'s net income for fiscal 2025 was −$438.0M, compared with −$522.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$184.8M. Over the past ten years it has ranged from −$615.1M (fiscal 2023) to $528.6M (fiscal 2021); the current reading is higher than 33% of that period. Vir Biotechnology, Inc. ranks 512th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$438.0M | — |
| FY2024 | −$522.0M | — |
| FY2023 | −$615.1M | — |
| FY2022 | $515.8M | (2.41%) |
| FY2021 | $528.6M | — |
| FY2020 | −$298.7M | — |
| FY2019 | −$174.7M | — |
| FY2018 | −$115.9M | — |
| FY2017 | −$69.9M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$96.3M | — |
| Jun 2026 | $80.1M | — |
| Mar 2026 | −$125.7M | — |
| Dec 2025 | −$42.9M | — |
| 30 more quarters | Free account |
Against its own ten years
Low −$615.1M
High $528.6M
Ten-year median
−$174.7M
Current reading's percentile
33
Net income against peers
| Company | Net income |
|---|---|
| ZYME Zymeworks Inc. compare | $43.3M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $16.3M |
| VIR Vir Biotechnology, Inc. | −$184.8M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| REPL Replimune Group, Inc. compare | −$271.0M |
| IMNM Immunome, Inc. compare | −$282.6M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
| BHVN Biohaven Ltd. compare | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VIR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement